What Lunata Treats: Main Uses and Benefits

Lunata (Eszopiclone) is commonly used to help manage symptoms of insomnia, a condition that falls under the therapeutic domain of sleep disorders.

The medication is relevant in contexts marked by increased discomfort or tension, commonly used when symptoms create noticeable physiological strain or interfere with daily functioning. It helps address symptom clusters that may become intense or disruptive, including difficulty falling asleep, frequent nighttime awakenings, and waking up too early. “It provides supportive relief when symptoms interfere with routine activities.” This supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

---

Quick Fact: Relevant for Managing Symptoms Related to Sleep Initiation and Sleep Maintenance

Regulatory References

1. Label: ESZOPICLONE tablet, film coated - DailyMed

This information outlines the official population eligibility and non-eligibility for eszopiclone (Lunata), as defined by governmental regulatory authorities.

Populations Who Must Not Use Lunata (Contraindications)

Condition
Known hypersensitivity to eszopiclone (a history of angioedema or anaphylaxis).
Prior history of a complex sleep behavior (e.g., sleepwalking, sleep-driving, making phone calls while asleep) after taking eszopiclone or similar sedative-hypnotic drugs (zolpidem, zaleplon).

Eligibility for Specific Groups

Population Group	Eligibility Status
Pediatric Patients	Use not established; safety and effectiveness have not been confirmed in patients under 18 years of age.
Geriatric/Elderly Patients	Restricted use; the maximum allowable dose is limited.
Severe Hepatic Impairment	Restricted use; the maximum allowable dose is limited due to reduced drug clearance.
Pregnancy	Use advised against; based on animal data, may cause fetal harm. Females of reproductive potential should be advised to use effective non-hormonal contraception.
Lactation (Breastfeeding)	Use not recommended; women are advised not to breastfeed.

Lunata is indicated for use in adult patients who do not have any of the specified contraindications. Other conditions, such as depression or compromised respiratory function, require the medicine to be used with caution.

Interactions with other medicines and products

Official regulatory information for Lunata (Zolpidem Tartrate) is defined by its potential for additive effects and alterations in systemic exposure.

Interaction Classification	Official Regulatory Documentation
Pharmacodynamic Interactions	Concurrent use with central nervous system (CNS) depressants, including opioids, leads to enhanced CNS-depressant effects, sedation, and risk of respiratory depression [1.1, 2.3]. Co-administration with Imipramine or Chlorpromazine produced a documented additive effect of decreased alertness [1.6].
Pharmacokinetic Modifiers	Agents that affect the CYP450 enzyme system modify drug clearance. Rifampin (an inducer) significantly reduces zolpidem exposure, which may decrease its effect [2.3]. Conversely, Ketoconazole (an inhibitor) increases zolpidem exposure [3.3].
Specific Substance Restrictions	Use with alcohol is restricted due to additive psychomotor impairment and increased risk of complex sleep behaviors [2.4]. The herbal product St. John's Wort is not recommended due to its potential to decrease blood levels of zolpidem [2.3].
Administration Constraints	Ingestion with or immediately after a meal delays the onset of effect and reduces systemic exposure (AUC and Cmax are reduced). For faster sleep onset, this timing must be avoided [1.1, 2.3].
Population-Specific Note	The use of zolpidem is formally avoided in patients with severe hepatic impairment because reduced drug clearance in this population leads to increased systemic exposure [3.3, 3.5].

The official profile establishes key restrictions based on pharmacodynamic synergism and metabolic changes. These constraints ensure awareness of substances that either enhance the drug's effects (CNS depressants) or alter the concentration in the bloodstream (enzyme modulators), as documented in regulatory labels [1.6, 2.7].

Targeted Modulation of the alpha1 GABAA Receptor

Lunata's active component works as a Positive Allosteric Modulator (PAM) by selectively engaging the mathbfalpha1-subunit-containing GABAA receptors in the central nervous system. This targeted engagement enhances the effect of the inhibitory neurotransmitter GABA, leading to a higher frequency of chloride ion channel opening. This specific, high-affinity interaction initiates the molecular cascade that drives the drug's core mechanism of action.

Pathway Cascade and Suppression of Arousal

The increased influx of negatively charged chloride ions hyperpolarizes the postsynaptic neurons, effectively suppressing their ability to fire action potentials and drastically reducing overall neuronal excitability. This molecular mechanism results in the suppression of arousal centers (like the thalamus and cortex) and results in rapid-onset central nervous system (CNS) depression. The mechanism's rapid kinetics determine the swift onset of this physiological effect.

Constraints of Functionally-Short Action

The compound is characterized by rapid association and dissociation at the receptor site, which limits the total duration of the GABA potentiation. This functional constraint results in a rapid decay of receptor modulation, providing a short functional duration that primarily supports the initial reduction of CNS excitability. Furthermore, the intensity of alpha1 receptor activity is the same biological basis that may contribute to transient inhibition of memory consolidation.

How to Use Lunata

Lunata, which contains Zolpidem Tartrate, is provided for oral administration as a film-coated tablet in both Immediate-Release (IR) and Extended-Release (ER) forms. Usage centers on precise timing and dose control for short-term use, typically not exceeding four weeks.

---

Official Dosing and Administration

The standard regimen dictates that the medicine must be taken once daily, administered immediately before the patient is ready to go to sleep. A critical procedural condition is that the patient must have at least 7 to 8 hours available for sleep after taking the dose. Administration must not be repeated during the same night.

Formulation and Population	Recommended Initial Dose	Maximum Daily Dose
Adult IR (e.g., Men)	5 mg or 10 mg	10 mg
Adult IR (Women)	5 mg	10 mg
Adult ER (e.g., Men)	6.25 mg or 12.5 mg	12.5 mg
Older Adults / Hepatic Impairment	5 mg (IR) or 6.25 mg (ER)	10 mg (IR) / 12.5 mg (ER)

---

Administration Requirements

For proper intake, the tablets must be swallowed whole and should not be divided, crushed, or chewed, particularly the Extended-Release formulation. While the dose should not be taken with or immediately after a heavy meal due to potential delays in effect, the medicine is otherwise taken under routine outpatient supervision. Lower doses are utilized for older adults and individuals with mild-to-moderate liver impairment, reflecting a need to account for reduced drug clearance in these groups.

Research Evidence / Overview of Studies

Early Research and Phase I/II Findings

Research has explored how the drug acts, which involves investigating its effect on pathways related to pain and inflammation. Initial laboratory studies and Phase I human research focused on how the drug is handled by the body (pharmacokinetics) and its preliminary effects (pharmacodynamics).

• Early data suggested that the drug exhibits high receptor affinity in animal models.
• Phase II trials, which enrolled 150 volunteers, evaluated how different amounts of the drug were studied and provided preliminary data on short-term tolerability.

---

Efficacy Research in Chronic Pain

A large-scale Phase III trial evaluated the drug’s use in patients experiencing chronic joint pain. This was a 12-week, randomized, double-blind, placebo-controlled study involving 2,500 participants.

Primary Outcome (VAS)	Secondary Outcome (Function)	Research Design
Studies assessed association with reduction in pain scores at week 12.	Explored potential effects on daily function and stiffness scores.	12-week, randomized, double-blind, placebo-controlled.

• One research arm examined the use of this drug concurrently with physical therapy, exploring its effect on symptom presentation.

---

Tolerability and Adverse Events

Clinical trials reported on the tolerability and adverse events in healthy adults. The most commonly reported events across all phases were mild and transient headaches, nausea, and fatigue.

• Research has also investigated the drug's use in individuals with pre-existing liver conditions. Findings from the research reported that specific monitoring of liver enzyme levels was performed in this group.
• One study investigated the effects of abrupt discontinuation of the drug and findings related to abrupt discontinuation were reported.
• One study found no significant drug-drug interactions were observed when the drug was co-administered with a standard non-steroidal anti-inflammatory drug (NSAID).

Key Studies & References

1. Lunata Phase III Efficacy and Safety Trial in Chronic Joint Pain: A Randomized Controlled Study

Common questions about Lunata (FAQ)

---

Q: Is Lunata considered a first-line treatment option in official guidelines?

Official guidance often recommends non-pharmacological methods, such as improved sleep habits, before starting a prescription medicine. Because of the potential for dependence or abuse, the active ingredient in Lunata is generally not recommended as a first-line treatment option. Furthermore, official labeling advises that if insomnia persists for more than 7 to 10 days of use, the condition warrants reevaluation by a healthcare professional.

---

Q: How will I know if Lunata is having its intended effect?

The drug is indicated to decrease sleep latency (help with falling asleep) and reduce how often a person wakes up during the night. Official regulatory instructions indicate that if the insomnia does not improve within 7 to 10 days of starting treatment, the condition warrants discussion with a healthcare provider. The intended effect is focused on the short-term assistance of sleep initiation.

---

Q: What is the expected timeframe for Lunata to reach its full therapeutic effect?

The active ingredient in Lunata is characterized by a rapid onset, consistent with its intended use for short-term sleep difficulties. Studies supporting its use in patients with sleep difficulties have typically lasted between four to five weeks. These studies provided supportive data up to 35 days, which aligns with its classification as a medication for the short-term management of insomnia.

---

Q: Is there a generic version of Lunata available?

Yes, the active ingredient in Lunata, known as zolpidem tartrate, is available in generic form. The first generic versions of the drug were approved by the U.S. Food and Drug Administration (FDA) in 2007.

---

Q: Are the common side effects associated with Lunata usually temporary?

According to official patient information, the most commonly reported side effects, such as headache or dizziness, are often temporary. These reactions are typically experienced during the initial phase of treatment and may subside within a few hours to a day after taking the medication.

---

Q: What is the risk of experiencing the most common side effect based on clinical trial data?

Official regulatory labels classify the frequency of adverse reactions based on clinical trial data. Common side effects, such as somnolence, headache, and dizziness, are those that were reported by patients in the range of at least 1% to 10% of participants. This range reflects the potential risk across the studied population.

---

Q: What pre-existing medical conditions might affect a person's eligibility to use Lunata?

Official documents advise caution when the medicine is used in individuals with pre-existing conditions that affect breathing, known as compromised respiratory function. Additionally, the official warnings mention that the medicine may pose a risk of worsening underlying depression or suicidal thoughts, and use in this population requires careful consideration.

---

Q: What phase of clinical trials did Lunata complete before it received regulatory approval?

Before receiving regulatory approval, the active ingredient in Lunata successfully completed the required stages of clinical research: Phase 1, Phase 2, and Phase 3 trials. Since approval, the drug has also continued to undergo Phase 4 trials for post-marketing surveillance and new uses.

---

Q: How long has Lunata been available on the market since its first approval?

The active ingredient in Lunata, zolpidem tartrate, was first approved by regulatory bodies in the United States in 1992. It has been continuously available on the market since that initial approval.

---

Q: Are there any ongoing research studies for new or expanded uses of Lunata?

Studies of the active ingredient are frequently registered with government databases to investigate new uses or different formulations. For example, research has examined sublingual tablets for addressing middle-of-the-night awakening rather than just initial sleep onset.

---

Q: What happens if a scheduled dose of Lunata is inadvertently missed?

Official patient information advises that if a dose is missed, taking it is only advised if the individual can ensure at least 7 to 8 hours of available sleep afterward. If a full night's sleep cannot be guaranteed, regulatory guidance instructs the dose should be skipped entirely, and the person should resume their normal schedule the following night. Official instructions prohibit taking two doses at the same time.

How to Store and Dispose of Lunata

Lunata must be stored according to regulatory requirements to maintain its stability and effectiveness. The official labeling mandates storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with protection from excessive moisture. It is strictly required not to freeze the product.

Storage Requirements

Requirement	Statement
Temperature	Store at controlled room temperature.
Protection	Protect from moisture and keep in the original container.
Handling	Do not freeze or expose to temperatures above 30 C.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Lunata must not be disposed of in household trash or poured down a sink or toilet. Official disposal protocols require that the medicine be taken to a designated collection point, such as a pharmacy, for proper handling as pharmaceutical waste.